2-phenyl-pyrazolo[1,5-a]pyridine-3-carbaldehyde | 71727-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-phenyl-pyrazolo[1,5-a]pyridine-3-carbaldehyde
• 英文别名: 2-phenylpyrazolo[1,5-a]pyridine-3-carbaldehyde
• CAS: 71727-37-2
• 化学式: C₁₄H₁₀N₂O
• 分子量: 222.246
• InChiKey: GSGVFADOGIAWSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-phenyl-pyrazolo[1,5-a]pyridine-3-carbaldehyde 在 sodium hydroxide 、 氯化亚砜 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-[(2R)-2-(2-羟基乙基)-1-哌啶基]-3-(2-苯基吡唑并[1,5-a]吡啶-3-基)-,(2E)-2-丙烯-1-酮
  参考文献：
  名称：

  Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist

  摘要：

  Novel 2-phenylpyrazolo[1,5-a]pyridine-3-acryloylamides were synthesized and evaluated for diuretic activities. FK453 (1d), the most potent compound in this series, was found to be a potent and selective adenosine A(1) receptor antagonist, whereas 1e, the (S)-enantiomer of FK453, was a weak and non-selective adenosine antagonist. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00368-x
• 作为产物：
  描述：

  2-Phenyl-pyrazolo[1,5-a]pyridine-4-carboxylic acid ethyl ester 在 氢溴酸 、 三氯氧磷 作用下， 生成 2-phenyl-pyrazolo[1,5-a]pyridine-3-carbaldehyde
  参考文献：
  名称：

  Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist

  摘要：

  Novel 2-phenylpyrazolo[1,5-a]pyridine-3-acryloylamides were synthesized and evaluated for diuretic activities. FK453 (1d), the most potent compound in this series, was found to be a potent and selective adenosine A(1) receptor antagonist, whereas 1e, the (S)-enantiomer of FK453, was a weak and non-selective adenosine antagonist. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00368-x

文献信息

• Pharmaceutically useful pyrazolopyridines
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04925849A1

  公开（公告）日：1990-05-15

  The disclosure deals with a pyrazolopyridine compound of the formula ##STR1## wherein the variables are defined in the specification. The compounds are useful as a diuretic, antihypertensive agent, etc.

  该披露涉及公式为##STR1##的吡唑吡啶化合物，其中变量在规范中定义。这些化合物可用作利尿剂、降压药剂等。
• Pyrazolopyridine compound and processes for preparation thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04994453A1

  公开（公告）日：1991-02-19

  The disclosure deals with pyrazolopyridine compounds of the formula ##STR1## wherein the variables are defined in the specification. The compounds are useful in the treatment of bronchial asthma, immunosuppression, diabetes, etc.

  该披露涉及公式为##STR1##的吡唑吡啶化合物，其中变量在规范中定义。这些化合物在治疗支气管哮喘、免疫抑制、糖尿病等方面是有用的。
• Method of treating kidney disease using pyrazolopyridine compound
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05102869A1

  公开（公告）日：1992-04-07

  The invention relates to a method for the treatment of renal toxicity, nephrosis or nephritis which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

  这项发明涉及一种治疗肾毒性、肾病或肾炎的方法，包括给予所述发明的吡唑吡啶化合物的有效量。
• Pharmaceutical method of treatment using pyrazolopyridine compound
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05102878A1

  公开（公告）日：1992-04-07

  The invention relates to a method for the treatment of ailments which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

  这项发明涉及一种治疗疾病的方法，包括给予所述发明的吡唑吡啶化合物的有效量。
• Pyrazolopyridine compounds which have useful pharmaceutical utility
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05234930A1

  公开（公告）日：1993-08-10

  This invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack or angina pectoris, said compounds being of the formula ##STR1## wherein the radicals are defined in the claims.

  本发明涉及一种吡唑吡啶化合物，用于治疗忧郁症、心力衰竭、高血压、肾功能不全、肾毒性、肾病综合征、肾炎、水肿、肥胖症、支气管哮喘、痛风、高尿酸血症、婴儿猝死综合症、免疫抑制、糖尿病、心肌梗死、血栓形成、梗阻、动脉硬化闭塞、血栓性静脉炎、脑梗死、短暂性脑缺血发作或心绞痛。该化合物的分子式为##STR1## 其中基团的定义见权利要求。